Andreas Hochhaus - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Andreas Hochhaus's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Andreas Hochhaus
Verified
Chief Editor, Blood Cancer Journal
Beats
Climate Crisis, Islam , SEO, Cambodia, General News , Social Media
consumer, health
Content
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results | Leukemia
By Andreas Hochhaus Verified, Dong-Wook Kim, Jorge Cortés, Koji Sasaki, Michael J. Mauro, Timothy Hughes, Massimo Breccia, Moshe Talpaz, Yeow Tee Goh, Daniel DeAngelo, Fabian Lang, Michael C. Heinrich, Meng Cao| Nature Verified AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN) | Leukemia
By Kirsi Manz, Florian H. Heidel, Steffen Koschmieder, Frank Stegelmann, Andreas Hochhaus Verified, Haifa Kathrin Al-Ali, Andreas Reiter, Gernot Beutel, Konstanze Döhner| Nature Verified AbstractMyeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients’ quality of life and ability to perform daily activities. Recent studies showed differences in the perception of physician- versus patient-reported symptom burden. However, studies directly comparing patient- and physician-reported ratings are lacking.
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results | Leukemia
By Andreas Hochhaus Verified, Dong-Wook Kim, Jorge Cortés, Koji Sasaki, Michael J. Mauro, Timothy Hughes, Massimo Breccia, Moshe Talpaz, Yeow Tee Goh, Daniel DeAngelo, Fabian Lang, Michael C. Heinrich, Meng Cao| Nature Verified AbstractAsciminib is the first approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP). The present final analysis of the phase 1, open-label, nonrandomized trial (NCT02081378) assessed the long-term safety, tolerability, and antileukemic activity of asciminib in 115 patients with chronic myeloid leukemia in chronic phase without the BCR::ABL1T315I mutation who received asciminib 10–200 mg twice daily (BID) or 80–200 mg once daily (cutoff: March 14, 2023).
Company Info
Blood Cancer Journal
Hoboken, New Jersey, United States
'+1 201-748-6000